Nuclear medicine veteran Randy Weatherhead has been named vicepresident of marketing for the nuclear medicine division of SiemensMedical Systems in Hoffman Estates, IL. Weatherhead fills a positionpreviously held by Robert Lytle, who died in a plane
Nuclear medicine veteran Randy Weatherhead has been named vicepresident of marketing for the nuclear medicine division of SiemensMedical Systems in Hoffman Estates, IL. Weatherhead fills a positionpreviously held by Robert Lytle, who died in a plane crash earlierthis year (SCAN 5/10/95).
Weatherhead joins Siemens after a two-year stint with ADACLaboratories, where he was senior marketing manager. Prior toADAC, he was vice president of marketing at Sopha Medical Systems.
Weatherhead said his goal at Siemens is to grow the nucleardivision's market share, which stands at 21% globally. He seesthe company's investments in detector technology and computerworkstations as particularly important.
"We have an extensive distribution system worldwide, withthe largest service organization of any nuclear medicine company,"Weatherhead said. "We should be able to increase our marketshare substantially over the next few years."
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.